Compare EVCM & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | ADMA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | 647 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2021 | 2012 |
| Metric | EVCM | ADMA |
|---|---|---|
| Price | $12.29 | $8.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $10.67 | ★ $25.67 |
| AVG Volume (30 Days) | 168.5K | ★ 2.6M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.45 | N/A |
| EPS | 0.04 | ★ 0.19 |
| Revenue | ★ $588,907,000.00 | $42,219,783.00 |
| Revenue This Year | $7.39 | $27.46 |
| Revenue Next Year | $5.84 | $22.11 |
| P/E Ratio | $303.00 | ★ $45.79 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $7.66 | $7.21 |
| 52 Week High | $14.41 | $20.46 |
| Indicator | EVCM | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 43.53 |
| Support Level | $10.89 | $8.20 |
| Resistance Level | $12.39 | $8.97 |
| Average True Range (ATR) | 0.61 | 0.26 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 83.38 | 28.57 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.